Aortic stenosis prevention

Jump to navigation Jump to search


Resident
Survival
Guide

Aortic Stenosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Aortic Stenosis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Cardiac Stress Test

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Cardiac Catheterization

Aortic Valve Area

Aortic Valve Area Calculation

Treatment

General Approach

Medical Therapy

Surgery

Percutaneous Aortic Balloon Valvotomy (PABV) or Aortic Valvuloplasty

Transcatheter Aortic Valve Replacement (TAVR)

TAVR vs SAVR
Critical Pathway
Patient Selection
Imaging
Evaluation
Valve Types
TAVR Procedure
Post TAVR management
AHA/ACC Guideline Recommendations

Follow Up

Prevention

Precautions and Prophylaxis

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Aortic stenosis prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Aortic stenosis prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Aortic stenosis prevention

CDC on Aortic stenosis prevention

Aortic stenosis prevention in the news

Blogs on Aortic stenosis prevention

Directions to Hospitals Treating Aortic stenosis prevention

Risk calculators and risk factors for Aortic stenosis prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Mohammed A. Sbeih, M.D. [2]; Usama Talib, BSc, MD [3]

Overview

The risk of developing aortic stenosis following rheumatic heart disease can be minimized with early antibiotic therapy among patients with documented streptococcal pharyngitis (strep throat).[1] Bicuspid aortic valve disease is a congenital variant and cannot be prevented. As for calcific aortic stenosis, a number of small, observational studies have demonstrated an association between lowering cholesterol levels and decreasing the progression of the aortic stenosis;[2] however, randomized clinical trials have failed to corroborate these findings.[3][4][5]

References

  1. Dajani A, Taubert K, Ferrieri P, Peter G, Shulman S (1995). "Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association". Pediatrics. 96 (4 Pt 1): 758–64. PMID 7567345.
  2. Moura LM, Ramos SF, Zamorano JL; et al. (2007). "Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis". J. Am. Coll. Cardiol. 49 (5): 554–61. doi:10.1016/j.jacc.2006.07.072. PMID 17276178.
  3. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K; et al. (2008). "Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis". N Engl J Med. 359 (13): 1343–56. doi:10.1056/NEJMoa0804602. PMID 18765433.
  4. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB; et al. (2005). "A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis". N Engl J Med. 352 (23): 2389–97. doi:10.1056/NEJMoa043876. PMID 15944423.
  5. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J, ASTRONOMER Investigators (2010). "Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial". Circulation. 121 (2): 306–14. doi:10.1161/CIRCULATIONAHA.109.900027. PMID 20048204.


Template:WikiDoc Sources CME Category::Cardiology